Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.

Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.

By hijacking a process that cells use to keep themselves shipshape, targeted protein degradation has become a hot new area of drug development. In Vivo takes an in-depth look at the field ahead of a wave of data expected this year from early candidates that will give some insight into whether this strategy will truly open a new way to combat disease.

Affimed looks to build on the splash at last year’s American Association for Cancer Research meeting next month, while BioNTech aims to prove its immunotherapy capabilities with a CAR-T candidate.